ClinicalTrials.gg
RecruitingNCT07743294Updated Aug 3, 2026

Effect of Preoperative Rehabilitation Exercise on Improving Postoperative Lymphedema, Quality of Life and Care Needs in Patients With Breast Cancer Surgery

An interventional study of Preoperative Upper Limb Rehabilitation Exercise and Standard Nursing Care and Education in Breast Cancer and Rehabilitation, sponsored by National Taiwan University Hospital. Recruiting at 2 sites in Taiwan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Jun 2024, registered Jul 2026).
  • Started Jun 2024; still recruiting 2 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Non-randomized
Ages
20 Years and older
Sex
Female
01

Study summary

Breast cancer is one of the most common cancers among women worldwide, with surgery being a primary treatment. However, surgical tumor resection combined with lymph node dissection often leads to upper extremity lymphedema as a complication. This study aims to evaluate the effectiveness of preoperative rehabilitation exercise on upper limb function, lymphedema severity, quality of life, and post-discharge care needs in breast cancer patients undergoing surgery.

Participants will be assigned to either an experimental group receiving individualized preoperative rehabilitation exercise instruction or a control group receiving standard clinical nursing education. Outcomes will be measured across seven time points from pre-operation up to one year post-surgery.

Read the detailed description

Background:

Surgical resection combined with axillary lymph node dissection in breast cancer patients frequently causes upper extremity lymphedema, negatively impacting physical function and quality of life. Implementing upper limb rehabilitation exercises prior to surgery may facilitate functional recovery and reduce postoperative complications.

Objectives:

  1. To evaluate the effect of preoperative upper limb rehabilitation exercise on reducing postoperative lymphedema in patients with breast cancer.
  2. To examine changes in quality of life and home care needs following preoperative rehabilitation intervention.
  3. To analyze factors influencing upper extremity function, lymphedema severity, quality of life, and care needs among breast cancer surgical patients.

Methods \& Procedures:

This longitudinal quasi-experimental study will recruit 105 patients scheduled for tumor resection with axillary lymph node dissection at National Taiwan University Hospital and National Taiwan University Hospital Cancer Center.

  • Experimental Group: Receives individualized preoperative instruction and guidance on upper limb rehabilitation exercises starting preoperatively.
  • Control Group: Receives routine clinical nursing education preoperatively or on postoperative Day 1 according to standard ward procedures.

Data Collection Timeline:

Data will be collected at seven time points:

  1. Pre-operation (1 week / 1 day prior to surgery)
  2. Postoperative Day 1
  3. Postoperative Week 2 (first clinic visit)
  4. Postoperative Week 4
  5. Postoperative Month 3
  6. Postoperative Month 6
  7. Postoperative Year 1

Assessment Parameters:

Measurements include arm circumference, handgrip strength, shoulder range of motion, functional activities of daily living (ADL), lymphedema-related symptoms, quality of life, and care needs. Descriptive statistics and Generalized Estimating Equations (GEE) will be used to analyze treatment outcomes over time.

02

Conditions studied

  • Breast Cancer and Rehabilitation

Keywords

  • Lymphedema
03

In context

Breast Neoplasms

14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

This study's planned enrollment of 105 is above the median of 72 across 10,896 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,615 studies on the registry; 576 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with malignant breast cancer confirmed by post-surgical tissue examination.
  • Receiving primary surgery, including tumor resection combined with axillary lymph node dissection.
  • Age 20 years or older.
  • Conscious, able to communicate in Mandarin or Taiwanese, aware of diagnosis, capable of completing questionnaires and participating in interventions, and signed .

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairment or unaware of diagnosis, unable to complete questionnaires or correctly execute intervention measures.
  • Patients in the control group who independently schedule outpatient rehabilitation after returning home.
  • Unable to communicate in Mandarin or Taiwanese.
  • Undergoing breast reconstruction surgery.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Experimental Group: Preoperative Exercise

    Participants in this group receive individualized instruction and guidance on upper limb rehabilitation exercises starting 1 day prior to surgery.

    Behavioral: Preoperative Upper Limb Rehabilitation Exercise

  • Active comparator
    Control Group: Standard Care

    Participants in this group receive routine clinical nursing education preoperatively or on postoperative Day 1 according to standard ward procedures.

    Other: Standard Nursing Care and Education

Interventions

  • BehavioralPreoperative Upper Limb Rehabilitation Exercise

    Individualized instruction and guidance on upper limb rehabilitation exercises starting 1 day prior to surgery to reduce postoperative lymphedema and improve physical function.

  • OtherStandard Nursing Care and Education

    Routine clinical nursing education executed preoperatively or on postoperative Day 1 according to standard ward procedures.

06

What researchers measure

Primary outcomes

  1. Postoperative Upper Extremity Lymphedema Severity (Arm Circumference)

    Measured by changes in upper extremity arm circumference (in centimeters) at standardized anatomical points to evaluate lymphedema severity.

    Time frame: Baseline (1 day pre-operation), Postoperative Day 1, Week 2, Week 4, Month 3, Month 6, and Year 1

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect participant privacy and maintain data confidentiality in accordance with institutional review board (IRB) guidelines and informed consent agreements.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 2,661 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 30 months is close to that.

Counting every sponsor, half of 2,771 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2026
First posted
Aug 3, 2026
StartActual
Jun 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07743294
Responsible party
Sponsor
First posted
Aug 3, 2026
Start date
Jun 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 3, 2026

Study contacts

Meng-Ping Hsiao
Contact
A00708@ntucc.gov.tw
+886-919865349

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion